Prevalence of RET Mutations in Lung and Thyroid Cancers

Alexander E. Drilon, MD, discusses the prevalence of <em>RET</em> fusions and mutations in patients with cancer, including lung and thyroid cancers.

Alexander E. Drilon, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the prevalence ofRETfusions and mutations in patients with cancer, including lung and thyroid cancers.

In lung cancer, or more specifically non—small cell lung cancer, where there are about 200,000 cases every year,RETmutations affect up to 2% of the population. In papillary thyroid cancer,RETmutations are found in 10% to 20% of patients.

In medullary thyroid cancer,RET